The diabetes tech firm plans stock repurchases and new product launches to drive long-term growth through 2030.
DexCom unveiled a growth strategy aiming for over 10% annual revenue growth through 2030, alongside margin expansion and stronger cash flow. The company will repurchase $1 billion of stock in 2026 and return at least 50% of annual free cash flow to buybacks moving forward.
Management highlighted the rollout of the G7 15 Day system later this year and the next-generation G8, expected around late 2027 or early 2028. The G8 is designed to be 50% smaller, more accurate, and lower cost than its predecessor.
Coverage expansion, particularly for type 2 diabetes patients not using insulin, is a key focus. DexCom expects Medicare decisions, broader U.S. payer adoption, and international reimbursement gains to increase covered lives significantly in the coming years.